Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transition from CBDV to Epidyolex in Rett syndrome with refractory epilepsy
ACTRN12624000948594Phase 2Active, not recruiting
- Sponsor
- Sydney Children's Hospitals Network
- Start
- Aug 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cannabidiol and cannabidivarin in Rett syndrome (RTT) and epilepsy (2 arms), sponsored by Sydney Children's Hospitals Network. Primary endpoint: Seizure frequency. Started Aug 2024; status: active, not recruiting.
02
Drugs
cannabidiolcannabidivarin
03
Conditions
Rett syndrome (RTT)epilepsy
Beyond the preview
Go deeper on ACTRN12624000948594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000948594.